Rationale: Acute respiratory distress syndrome (ARDS) is caused by widespread endothelial barrier disruption and uncontrolled cytokine storm. Genome-wide association studies (GWAS) have linked multiple genes to ARDS. Although mechanosensitive transcription factor Krüppel-like factor 2 (KLF2) is a major regulator of endothelial function, its role in regulating pulmonary vascular integrity in lung injury and ARDS-associated GWAS genes remains poorly understood.
Lungs are strategically vascularized to achieve efficient gas exchange. The endothelial lining of pulmonary blood vessels maintains a tight barrier between the overlying epithelium exposed to atmospheric gas and the underlying blood flow, and also ensures adequate oxygenation by regulating ventilation/perfusion relationships. Increased endothelial permeability results in parenchymal accumulation of leukocytes, protein, and extravascular water, all hallmarks of acute lung injury (ALI), which is clinically defined as the acute respiratory distress syndrome (ARDS), a devastating condition with high mortality rates (1, 2) . The normal function of the endothelium can be altered by infectious agents, mechanical factors, and chemicals. The final common pathway is compromised endothelial monolayer integrity (2) . Moreover, experimental models of ALI and human genome-wide association studies (GWAS) of ARDS suggest the central pathophysiologic role of cytokine storm (2) . Recent studies demonstrate that disruption of endothelial homeostasis contributes significantly to the uncontrolled cytokine storm in ARDS (3, 4) .
Endothelial barrier function is dynamically regulated by intercellular junctions and cytoskeletal remodeling, which are controlled by the activities of small GTPases, particularly Rho family of GTPases, such as Ras homolog gene family member A (RhoA), Cell Division Cycle 42 (Cdc42), and Rac1 (5, 6) . Specifically, Ras-related C3 botulinum toxin substrate 1 (Rac1 GTPase), in its activated or GTP-bound state, maintains endothelial monolayer integrity by stabilizing intercellular junctions and by formation of cortical actin (7, 8) . In contrast, Rac1 inactivation (guanosine diphosphate [GDP]-bound state) is linked to leaky vasculature (9) . Rac1 activity is dynamically modulated by biochemical activators (10) and biomechanical stimuli (11, 12) . However, it remains unclear whether transcription factors contribute to Rac1-mediated barrier protection.
Transcription factor Krüppel-like factor 2 (KLF2) of the zinc finger family of DNA-binding proteins has recently emerged as a major molecular switch that controls endothelial homeostasis (13) (14) (15) (16) . KLF2 is evolutionarily conserved between rodents and human and regulates arterial vascular tone by transactivating endothelial nitric oxide synthase (NOS3) and trans-repressing endothelin-1 (13, 14, 17) . KLF2 maintains blood fluidity by increasing thrombomodulin (TM) (13, 14, (17) (18) (19) . KLF2 was first cloned from lung tissues and is also known as lung Krüppel-like factor (20) . Genetic deletion of Klf2 in mice is embryonically lethal because of impaired blood vessel maturation and abnormalities in lung development (21) (22) (23) (24) . The putative role of KLF2 in inflammatory lung diseases remains poorly understood. We sought to determine if KLF2 plays a role during ALI via small GTPase signaling-mediated cytoskeletal remodeling.
We report that lung Klf2 expression is significantly reduced in vivo in rodent models of ALI induced by influenza virus, LPS, or high-tidal-volume mechanical ventilation, consistent with KLF2 reduction in human pulmonary microvascular cells (HMVEC) subjected to LPS, tumor necrosis factor (TNF)-a, or cyclic stretch. Capillary shear stress maintains the physiologic expression of microvascular KLF2 that is suppressed by TNF-a. The experiments further establish transcriptional regulation of small GTPases: KLF2 transactivates Rap guanine nucleotide exchange factor 3 (RAPGEF3, also known as EPAC1), which confers Rac1 activation and enhances endothelial barrier integrity. Moreover, endothelial KLF2 regulates multiple human ARDS candidate genes implicated by GWAS (25, 26) , particularly those associated with cytokine storm. KLF2 overexpression significantly ameliorates LPS-induced ALI in vivo. These results collectively provide the first evidence linking disruption of KLF2 signaling in the pathogenesis of inflammatory lung diseases and elucidate a new molecular mechanism by which KLF2 regulates microvascular barrier protection via small GTPase signaling.
Some of the results of these studies have been previously reported in the form of an abstract at the 2016 annual meeting of the American Thoracic Society (27) .
Methods

Animals and In Vivo KLF2 Overexpression
For the mouse models of virus-and bacteria-induced ARDS, C57BL/6J mice were anesthetized and then intratracheally instilled either with influenza A virus (A/WSN/33 [H1N1]) (500 pfu/mouse) or LPS (0.7 mg/kg body weight; Escherichia coli O55:B5). Animals were killed after 24 hours. For the rat model of ventilatorinduced lung injury, male Sprague Dawley rats were intubated and LPS (0.75 mg/kg) was administered via the endotracheal tube. Rats were rotated 90 degrees after each aliquot (supine, right decubitus, prone, and left decubitus) to achieve homogenous LPS distribution. Rats were then extubated for 24 hours and reintubated and ventilated for 8 hours in a volume control mode and randomly assigned to two groups: tidal volume of 12 ml/kg and respiratory rate of 60 breaths per minute (adjusted to keep end tidal CO 2 (28) to model viral-pneumonia-induced ARDS. As expected, influenza A virus caused lung inflammation evident by increased expression of Ccl2, Ccl4, Il6, and Cxcl2 (quantitative real-time polymerase chain reaction) ( Figure 1A ) and elevated cell counts/proteins in BAL fluid (see Figure E1A in the online supplement). Moreover, Klf2 expression was significantly reduced in the lungs with influenza A virus infection ( Figure 1A ). Second, mice were intratracheally administered with LPS to model bacteriainduced ARDS. Proinflammatory genes and increased cell counts/protein in BAL (see Figure E1B ) were induced in LPS-treated lung, accompanied by significant reduction in Klf2 ( Figure 1B) . A third animal model was developed to investigate the effect of high tidal volume ventilatory support, which is associated with ventilatorinduced lung injury in patients with ARDS (29) . Rats were first subjected to intratracheal administration of LPS for 24 hours, followed by intubation and mechanical ventilation at high (12 ml/kg) or low tidal volumes (6 ml/kg) for 8 hours. Figure 1C shows increased inflammation and reduced Klf2, accompanied by lung injury (see Figure E1C ) in the rat lungs subjected to high tidal volume ventilation. All animal models demonstrate significant reduction in Klf2 expression associated with lungs subjected to ALI.
Pathologic Cyclic Stretch and Inflammatory Stimuli Inhibit KLF2 in HMVEC
We then tested the hypothesis that endothelial KLF2 expression is dynamically regulated by vascular overdistention, such as that seen in high tidal volume ventilation. Cyclic stretch at 18% (nonphysiologic) was previously reported to cause vascular damage, such as enhanced endothelial permeability (30, 31) . KLF2 expression was measured in HMVEC subjected to 5% (A) Mice were infected with 500 multiplicity of infection of influenza A/WSN/H1N1 for 2 days and killed to collect lung tissues for RNA isolation followed by quantitative real-time polymerase chain reaction (qRT-PCR). mRNA expression for Il6, Ccl2, Ccl4, and Cxcl2 in H1N1-infected mice are significantly elevated, whereas Klf2 expression is decreased compared with control (ctrl) mice. n = 6. (B) Mice were intratracheally administrated with 0.7 mg/kg LPS for 24 hours and killed to collect lung tissues for RNA isolation followed by qRT-PCR. mRNA expression for Il6, Ccl2, Ccl4, and Cxcl2 are significantly elevated in LPS-challenged mice, whereas Klf2 expression is decreased compared with control (ctrl) mice. n = 5-9. (C) Rats were ventilated with a tidal volume of 12 ml/kg (high tidal volume) or 6 ml/kg (low tidal volume) for 8 hours after 24-hour LPS administration and then killed to collect lung tissues for RNA isolation followed by qRT-PCR. mRNA expression for Il6, Ccl2, Ccl4, and Cxcl2 in high tidal volume rats are significantly elevated, whereas Klf2 expression is decreased compared with low tidal volume rats. n = 4-9. All data are represented as fold change. Error bars represent 6 SEM. *P , 0.05, **P , 0.01, ***P , 0.001, Student's t test. Ccl2 = C-C motif chemokine ligand 2; Ccl4 = C-C motif chemokine ligand 4; Cxcl2 = C-X-C chemokine ligand 2; HTV = high tidal volume; LTV = low tidal volume.
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(physiologic) or 18% cyclic stretch for 24 hours. We detected a significant KLF2 reduction in HMVEC exposed to 18% circumferential stretch when compared with cells under static condition; 5% stretch has no effect on KLF2 expression (Figure 2A ). An 18% stretch-induced KLF2 suppression was not detected in endothelium isolated from other vascular beds (see Figure E2 ). To determine whether microvascular endothelial KLF2 is regulated by inflammatory stimuli associated with lung infections, KLF2 was measured in HMVEC treated with LPS and TNF-a. Treatment with LPS or TNF-a for 24 hours led to a significant reduction of KLF2 in HMVEC ( Figures 2B and 2C ), accompanied by increased expression of CCL2, IL-6, IL-8, and SELE (see Figure E3 ).
KLF2 Preserves Pulmonary Microvascular Barrier Function
Increased pulmonary vascular permeability is a hallmark of ARDS pathogenesis. To establish the putative role of KLF2 in governing pulmonary microvascular integrity, endothelial permeability was determined in HMVEC in which endogenous KLF2 expression was modulated. Monolayer integrity was measured by three independent methods in HMVEC, in which KLF2 is reduced by either gene-targeted small interfering RNAs (siRNAs) or overexpressed by adenoviruses. As shown in Figure 2D , KLF2-targeted siRNAs (siKLF2) reduced endogenous KLF2 mRNA by approximately 53%, and notably increased the intercellular gap formation (3.33% vs. 0.01% gap area in control subjects). Compromised monolayer integrity in KLF2-deficient HMVEC was further demonstrated by the elevated trans-monolayer permeability determined by an XPerT Assay (see Figure E4 ) (32) that quantifies the mass transport of macromolecular tracers (A488-streptavidin) across a cell monolayer. Figure 2E demonstrates that macromolecule transport was significantly higher in HMVEC treated with siKLF2. The role of KLF2 in maintaining microvascular integrity is also supported by the real-time measurement of transendothelial electrical resistance (TER). Knockdown of endogenous KLF2 significantly reduced TER in HMVEC monolayer by approximately 47% ( Figure 2F ) at 2 days. In contrast, overexpression of KLF2 using adenoviral Figure 2G ) and resulted in a significant increase in TER ( Figure 2H ), suggesting strengthening of endothelial barrier function by KLF2 induction.
KLF2 Activates Rac1 in HMVEC
Activation of small GTPase Rac1 is associated with stabilized cortical actin and increased vascular barrier function (7, 33) . We hypothesized that endothelial KLF2 mediates vascular monolayer integrity by modulating Rac1 activity. Rac1 activation is determined by the activated GTP-bound state and inactive GDP-bound state (5) . As shown in Figure 3A , a GTPase pull-down assay detects an approximately 40% reduction of activated GTP-bound Rac1 as the result of KLF2 knockdown. Conversely, KLF2 overexpression significantly increases the GTP-bound Rac1 (2.5-fold) in HMVEC ( Figure 3B ). Notably, Rac1 mRNA levels are not affected by KLF2 knockdown or overexpression ( Figures 3C and 3D ). These data demonstrate that KLF2 is a novel indirect activator of small GTPase Rac1, given the insensitivity of Rac1 mRNA to KLF2 manipulation. 
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KLF2 overexpression enhanced RAPGEF3 mRNA transcription by approximately fourfold ( Figure 4C ) and increased protein expression by approximately threefold ( Figure 4D ). The up-regulation of endothelial RAPGEF3 by KLF2 was further validated by a complementary approach to induce KLF2 expression in HMVEC. In vitro transcription was used to prepare wild-type human KLF2 transcripts and mutant KLF2 transcripts in which the translation start codons (AUGs) were mutated to disrupt translation. RAPGEF3 was significantly increased in HMVEC transfected with wild-type KLF2 transcripts when compared with cells treated with AUGsmutated KLF2 transcripts ( Figure 4E ).
RAPGEF3 transactivation by KLF2 is further supported by the presence of multiple KLF2 binding sites in the human RAPGEF3 promoter. Encyclopedia of DNA Elements studies indicate an 896-bp region upstream of human RAPGEF3 as a putative promoter in which we identified five CACCC elements that are well-established KLF2 binding sequences (16) . Dualluciferase reporter assay was used to determine the activity of this putative human RAPGEF3 promoter and more importantly, to examine its response to KLF2. The assays were conducted using both wild-type RAPGEF3 promoter and a mutated sequence in which CACCC sites were replaced by GTACT to disrupt KLF2 binding ( Figure 4F ). Figure 4G demonstrates that human RAPGEF3 putative promoter increased the luciferase activity by approximately twofold when compared with the promoter-less control subjects; CACCC→GTACT mutation significantly abolished the RAPGEF3 promoter activity. KLF2 overexpression significantly increased luciferase expression on the wild-type promoter, and again, mutated putative KLF2 binding sites significantly diminished luciferase expression ( Figure 4H) . Moreover, the physical binding between KLF2 and RAPGEF3 promoter was confirmed by ChIP was performed with either a control IgG antibody or the antibody against HA followed by quantitative polymerase chain reaction using primers for RAPGEF3 promoter. n = 5. All data are represented as mean 6 SEM. *P , 0.05, **P , 0.01, ***P , 0.001, Student's t test. ACTB = actin-b; ChIP = chromatin immunoprecipitation; HA = hemagglutinin; HEK = human embryonic kidney; pRL-TK = Renilla luciferase control reporter vectors; SC = control siRNA; siRNA = small interfering RNA; WT = wild type.
chromatin immunoprecipitation polymerase chain reaction ( Figure 4I ).
KLF2 Promotes Rac1 Activation and Barrier Function by Transactivating Endothelial RAPGEF3
Additional experiments were conducted to delineate whether KLF2-mediated barrier protection is dependent on the RAPGEF3-Rac1 signaling. First, using RAPGEF3 knockdown, we detected a significant reduction of Rac1 activation (GTP-bound Rac1) ( Figure 5A ), accompanied with increased monolayer permeability ( Figure 5B ), establishing a significant role for RAPGEF3 in activating Rac1 and promoting monolayer integrity in HMVEC.
KLF2 overexpression significantly increased the RAPGEF3 mRNA ( Figure 5C ), RAPGEF3 protein ( Figure 5A ), GTP-bound Rac1 ( Figure 5A ), and HMVEC monolayer barrier function ( Figure 5B) ; notably, increased Rac1 activation and barrier function were reduced in KLF2-overexpressing cells by RAPGEF3 inhibition. Moreover, RAPGEF3 overexpression significantly promoted barrier function in HMVEC and partially restored the monolayer integrity in KLF2-deficient cells ( Figure 5D) . These data collectively demonstrate that RAPGEF3 contributes to increased Rac1 activation and enhanced monolayer integrity in HMVEC. In HMVEC, both NOS3 and TM were significantly reduced with KLF2 knockdown ( Figure 6A ). Conversely, KLF2 overexpression led to increased expression of NOS3 and TM ( Figure 6B ), demonstrating KLF2 positively regulates NOS3 and TM in lung microvascular endothelium.
In addition to cyclic stretch as the result of respiration, lung microvascular endothelia are subjected to tangential frictional C *** *** *** *** HMVEC were transfected with 50 nM siKLF2 or SC, followed by RAPGEF3 overexpression via transfection with RAPGEF3 transcripts. Quantification was conducted 48 hours after RAPGEF3 overexpression. n = 4. All data are represented as mean 6 SEM. *P , 0.05, **P , 0.01, ***P , 0.001, Student's t test. ACTB = actin-b; ad-ctrl = adenovirus control; ctrl = control; Rac1 = Ras-related C3 botulinum toxin substrate 1; siKLF2 = siRNA against KLF2; siRNA = small interfering RNA; TER = transendothelial resistance.
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force generated by blood flow. Figure 6C ). In addition, KLF2 direct downstream targets RAPGEF3, NOS3, and TM were induced by microvessel shear stress in HMVEC. It was reported that during ALI, TNF-a promotes shedding of glycocalyx (40), a putative flow sensor (41) . To investigate this, we examined the flowregulation of KLF2, RAPGEF3, NOS3, and TM in HMVEC stimulated by TNF-a. As shown in Figure 6C , TNF-a pretreatment (30 min; 50 ng/ml) had no effect on KLF2, RAPGEF3, NOS3, and TM expression in HMVEC under static conditions, but significantly reduced the flow-mediated induction of KLF2 (control, 3.29 6 0.13-fold; TNF-a, 1.35 6 0.14-fold), RAPGEF3 (control, 3.49 6 0.22-fold; TNF-a, 1.83 6 0.15-fold), NOS3 (control, 2.67 6 0.19-fold; TNF-a, 1.08 6 0.11-fold), and TM (control, 2.79 6 0.19-fold; TNF-a, 1.11 6 0.10-fold).
The in vivo expression of Rapgef3, Nos3, and Tm were determined in rodent lungs of ALI. All three Klf2 direct targets were significantly reduced in ARDS lungs induced by influenza A viruses ( Figure 6D ), high tidal volume ventilation ( Figure 6E ), and LPS ( Figure 7A ).
In Vivo Klf2 Overexpression Ameliorates LPS-induced ALI
We next used cationic polymers that effectively deliver KLF2-overexpressing constructs to mouse lungs. KLF2 induction in vivo increased the pulmonary expression of Rapgef3, Nos3, Tm, and reduced inflammatory biomarkers (Ccl2, Ccl4, and Cxcl2) in control mice ( Figure 7A ) and attenuated the reduction of Rapgef3, Nos3, and Tm and lessened the expression of inflammatory biomarkers in LPS-treated mouse lungs ( Figure 7A) . Protein measurements and cell counts in the BAL fluid demonstrate that LPS-induced lung injury was significantly lessened by KLF2 overexpression ( Figures  7B and 7C ).
KLF2 Regulates Genes Associated with Human ARDS In Vitro and In Vivo
Recent efforts in GWAS have identified approximately 25 candidate genes that contribute to the pathogenesis of and/or susceptibility to ARDS in humans (25, 26) . Ingenuity Pathway Analysis (IPA) is a system that transforms a list of genes of interest into a set of relevant networks based on reported biologic interactions (42) . Our IPA inquiry ( Figure 8A ) demonstrates that ARDS-associated GWAS genes and KLF2 form a highly interconnected network, indicating KLF2 regulation of IL6, IL8, angiotensin I-converting enzyme (ACE), NAD(P)H dehydrogenase, quinone 1 (NQO1), plasminogen activator inhibitor (SERPINE1/PAI-1), TNF, and nuclear factor-kB (NF-kB) inhibitor a (NFKBIA). Because IPA uses known biologic information not limited to microvascular endothelium, we have performed KLF2 overexpression experiments to establish the direct regulation of these ARDS genes by KLF2 in HMVEC. KLF2 induction resulted in significant reduction of inflammatory genes IL6, IL8, and TNF, vasoconstricting ACE, and antifibrinolytic SERPINE1 ( Figure 8B) . Moreover, the antioxidant reductase NQO1 and NF-kB inhibitor NFKBIA were significantly increased in HMVEC by KLF2 overexpression ( Figure 8B ). Expression of these ARDS GWAS genes was further determined in vivo in mouse lungs as a function of KLF2 expression. Consistent with the in vitro data in HMVEC, Ace, Il6, Il8, Serpine1, and Tnf were reduced, whereas Nqo1 and Nfkbia were increased in mouse lung as the result of KLF2 overexpression ( Figure 8C ). The regulation of these ARDS GWAS genes by KLF2 in vivo was also detected in LPS-treated mouse lungs ( Figure 8D ).
Discussion
Although KLF2 is abundantly expressed and was first cloned in lungs (20) , and is perhaps the critical transcription factor that determines endothelial quiescence (13-15, 17, 43-45) , whether KLF2 contributes to pulmonary vascular pathology remains poorly investigated. Herein, using rodent models of ALI, we demonstrate that endogenous KLF2 is significantly reduced in inflamed lungs subjected to influenza A virus, LPS, or high tidal volume ventilation. These in vivo results are in agreement with reduced KLF2 in vitro in HMVEC stimulated by TNF-a, LPS, or increased circumferential stretch. Our investigations further highlight an as yet unrecognized regulatory role of KLF2 in small GTPase signaling, particularly in Rac1 activation and microvascular barrier protection. KLF2 transcriptionally regulates RAPGEF3 (EPAC1) through its multiple CACCC sites in the promoter; RAPGEF3 mechanistically contributes to Rac1 activation and enhances barrier functions in KLF2-expressing cells. The contributing role of KLF2 in ALI is further supported by KLF2 regulation of a cohort of ARDS genes established by GWAS. Thus, not only is downregulation of KLF2 associated with vascular dysfunction in ALI, but also mechanistically plays a role in the reduced activity of Rac1. Moreover, KLF2 overexpression restores the expression of RAPGEF3 and a cohort of ARDS-associated GWAS genes and ameliorates LPS-induced lung injury in vivo.
The integration of genetic information and network modeling has been used to explore key biologic processes that contribute to clinical traits of common complex human diseases (46) . Consistent with a previous study (26) , our pathway analyses demonstrate that multiple GWAS-identified ARDS genes form a highly interconnected network and moreover, KLF2 can serve a hub gene to regulate many ARDS-associated genes. In addition to compromised vascular integrity, increased inflammation and amplified coagulation are hallmarks of ARDS pathogenesis. Our in vitro and in vivo results demonstrate that endogenous KLF2 contributes to the quiescent and anticoagulant phenotype of pulmonary microvascular endothelium by transcriptionally activating vascular protective genes NOS3 and TM, increasing antioxidant reductase NQO1 and NF-kB inhibitor NFKBIA, inactivating cytokines (IL-6, IL-8, TNF-a), and decreasing adhesion molecule expression (see Figure  E7) , and suppressing vasoconstrictive ACE and antifibrinolytic SERPINE1. RAPGEF3/ EPAC1 has recently emerged as a critical effector of endothelial homeostasis and cardiac remodeling; however, the molecular mechanisms of EPAC1 regulation remain poorly defined (47) . Our results demonstrate that KLF2 is a novel transcriptional regulator that maintains RAPGEF3 expression in endothelium.
In addition to barrier protection (7, 9), Rac1 GTPase has been linked to many other signal transduction pathways that govern cellular proliferation, migration, growth, differentiation, and apoptosis (5). Rac1 activity is dynamically regulated by numerous stimuli, such as hormones, cytokines, growth factors, and oxidative stress. Our data suggest transcription factors (e.g., KLF2) can actively control the on-off switch of Rac1 cycling between GTP-bound and GDPbound forms by regulating upstream activators of Rac1, such as RAPGEF3.
RAPGEF3 regulation by KLF2 is supported by RAPGEF3 modulation as the result of KLF2 manipulation and moreover, by the presence of five KLF2 binding sites (CACCC) in the RAPGEF3 promoter. In contrast, expression of other Rac1 upstream activators VAV2 and TIAM1 is not regulated by KLF2, consistent with low and absent CACCC sites in the promoter regions (one CACCC in human VAV2 and no CACCC in human TIAM1 promoter). RAPGEF5 and RAPGEF6, other members of RAS subfamily of GTPases, are not regulated by KLF2 in HMVEC (see Figure E8 ), in agreement with the lack of multiple CACCC sites in their promoter regions. Moreover, our results demonstrate that KLF2 does not significantly regulate mRNA expression of junctional proteins claudin 5 (CLD5), tight junction protein 1 (ZO-1), afadin (AF6), claudin-12 (CLD12), F11 receptor (JAM1), and occludin (OCLN) that are implicated in barrier function (see Figure E9) .
One unique feature of KLF2 is its sensitivity to physical stimuli. Endothelial KLF2 expression is greatly influenced by hemodynamic forces, particularly the shear stress generated by arterial blood flow (13, 17, 44, 48) . Lung microvasculature is exposed to considerable shear stress because of the small vessel radius (39) . Vascular endothelium is decorated by various membrane-bound macromolecules forming the glycocalyx that plays a major role in sensing blood flow (41) . Alterations in microvascular circulation (49) and more importantly, the loss of glycocalyx as the result of TNF-a have been reported during lung injury (40) . Our data suggest that continuous microvascular flow is a critical regulator of physiologic levels of endogenous endothelial KLF2 and its downstream targets. Moreover, TNF-a pretreatment significantly reduced the flow-sensitivity of KLF2 and the mechanoregulation of its downstream targets to microvascular shear stress in HMVEC. It is plausible that KLF2 reduction in diseased lungs is attributable to the disruption of microvascular blood flow and/or loss of endothelial glycocalyx and hence mechanosensation during ALI. It is important for future studies to determine KLF2 expression in lung tissue from patients with ARDS and precisely measure the pulmonary microvascular flow velocity in experimental lung injury models and moreover, in patients with ARDS.
The studies here further establish the regulation of KLF2 by cyclic stretch; (A) Ingenuity Pathway Analysis shows KLF2 plays a central role forming a highly interconnected network with genome-wide association studies-implicated acute lung injury/acute respiratory distress syndrome genes. (B) In human pulmonary microvascular cells overexpressing KLF2 via transfection with KLF2 transcripts (T7-KLF2), mRNA expression for ACE, IL6, IL8, SERPINE1, and TNFa are significantly decreased, whereas NQO1 and NFKBIA mRNA expression are up-regulated compared with T7-ctrl-transfected cells. n = 6-8. All data are represented as mean 6 SEM. mRNA expression for Ace, Il6, Il8, Serpine1, Tnf, Nqo1, and Nfkbia in mice transfected with KLF2-overexpressing plasmid or control plasmid without (C) or with LPS administration (D) demonstrated significant regulation by KLF2. n = 4-5. All data are represented as fold change. Error bars represent 6 SEM. **P , 0.01, ***P , 0.001, Student's t test. ACE = angiotensin I converting enzyme; ctrl = control; FTL = ferritin light chain; GSTM1 = glutathione S-transferase mu 1; LTA = lymphotoxin-a; NAMPT = nicotinamide phosphoribosyltransferase; NFE2L2 = nuclear factor, erythroid 2 like 2; NFKB1 = nuclear factor k B subunit 1; NFKBIA = NFKB inhibitor-a; NQO1 = NAD(P)H quinone dehydrogenase 1; PLAU = plasminogen activator, urokinase; SERPINE1 = serpin family E member 1; SOD3 = superoxide dismutase 3; TNF = tumor necrosis factor; VEGFA = vascular endothelial growth factor A.
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the implication is particularly relevant to lung vascular pathophysiology because pulmonary microvasculature is consistently exposed to physiologic cyclic stretch caused by continuous respiratory cycles and pathologic overdistention related to high-tidal ventilation (29) . In addition to compromised vascular integrity, dysfunctional pulmonary endothelium contributes significantly to the cytokine storm that drives the uncontrolled inflammatory response during ARDS (3, 4) , and that KLF2 regulates many ARDS GWAS genes (25, 26) . Our results demonstrate in HMVEC, KLF2 promotes antiinflammatory genes, and suppresses proinflammatory genes (IL6, IL8, TNF, and NFKBIA). In addition, KLF2 suppresses ACE in HMVEC, consistent with a study showing ACE knockout mice are protected from severe ALI (50) . ARDS is associated with uncontrolled activation of coagulation pathways and increased oxidants (2) , in agreement with KLF2 suppression of SERPINE1 that inhibits fibrinolysis, and KLF2 up-regulation of antioxidant NQO1. Furthermore, Klf2 hemizygous (Klf2 1/2 ) mice were reported to exhibit worsened LPS-induced sepsis symptoms (51) . Our results show that pretreatment of KLF2 overexpression significantly ameliorated LPS-induced lung injury. It is important for future studies to determine the timing for endothelium-specific restoration of KLF2 in inflamed lungs that could promote vascular health to alleviate ARDS, yet maintain appropriate vascular inflammation to fight pathogens. Recent efforts have shown that therapeutic nucleotides can be delivered to inflamed endothelium by vascular cell adhesion protein-1 targeted nanoparticles (52), which could be used for future investigations in developing therapeutics to restore pulmonary endothelial KLF2 in treating ARDS. n
